{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:47:34Z","timestamp":1781916454946,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Med-Life Discoveries, LP","award":["Med-Life Discoveries, LP"],"award-info":[{"award-number":["Med-Life Discoveries, LP"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rhizomelic chondrodysplasia punctata (RCDP) is a rare genetic disorder characterized by symptoms such as respiratory dysfunction, seizures, orthopedic issues, and neurodevelopmental delay. Potential therapeutics for RCDP warrant the development of clinical outcome assessments to assess the efficacy of treatment and the well-being of patients. Our study aimed to develop a valid quality-of-life (QOL) caregiver-reported survey instrument, RhizoQOL, to be used as a supportive endpoint in RCDP clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Development of the RhizoQOL survey tool included three RCDP caregiver focus groups to elicit concepts to serve as potential domains in a QOL survey instrument for RCDP, pilot survey development and initial testing, cognitive interviewing of revised survey drafts to determine content validity, as well as a three-month longitudinal study for reliability and internal consistency of the survey instrument.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-eight caregivers participated in the focus groups, reporting that concepts that could be appropriate domains of QOL in RCDP include psychosocial behavior, feeding symptoms, mobility symptoms, respiratory symptoms, seizures and related activity, and impact of treatment. Following pilot survey testing (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922) and stakeholder feedback, a revised pilot survey instrument was administered to five caregivers for cognitive interviewing. This resulted in a revised survey instrument with 31 question items, six domains, and a 1\u20135 Likert scale item response assessing frequency or severity of event in the question item. Longitudinal testing (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918) of the revised survey instrument found the average response score was 1.98\u2009\u00b1\u20090.97 for all question items, and a Cronbach\u2019s alpha value of 0.856, suggesting strong intra-survey question reliability. Using individual question item results from reliability testing, linear regression modeling, and testing for required magnitude of significant treatment effects, eight question items were removed from the survey instrument, resulting in a total of 23 question items within 6 discrete domains.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The final RhizoQOL survey instrument, consisting of 23 questions, assesses the symptoms and experiences of RCDP patients as observed by caregivers and serves as a novel clinical outcome assessment for RCDP therapeutic clinical trials to assess the impacts of RCDP and support the overall effectiveness of treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03660-0","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:43:55Z","timestamp":1743399835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and evaluation of RhizoQOL, a quality-of-life caregiver-reported survey for rhizomelic chondrodysplasia punctata, a rare peroxisomal disorder"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0913-7738","authenticated-orcid":false,"given":"Mousumi","family":"Bose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahra C.","family":"Anglade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea I.","family":"Donlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian L.","family":"Kerrihard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel S.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn A.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"1","key":"3660_CR1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s13023-021-01889-z","volume":"16","author":"T Luisman","year":"2021","unstructured":"Luisman T, Smith T, Ritchie S, Malone KE. Genetic epidemiology approach to estimating birth incidence and current disease prevalence for rhizomelic chondrodysplasia punctata. Orphanet J Rare Dis. 2021;16(1):300.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3660_CR2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/ng0497-381","volume":"15","author":"PE Purdue","year":"1997","unstructured":"Purdue PE, Zhang JW, Skoneczny M, Lazarow PB. Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTS2 receptor. Nat Genet. 1997;15(4):381\u20134.","journal-title":"Nat Genet"},{"issue":"3","key":"3660_CR3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF00711817","volume":"17","author":"RJA Wanders","year":"1994","unstructured":"Wanders RJA, Dekker C, Hovarth VAP, Schutgens RBH, Tager JM, van Laer P, et al. Human alkyldihydroxyacetonephosphate synthase deficiency: a new peroxisomal disorder. J Inherit Metab Dis. 1994;17(3):315\u20138.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"3660_CR4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ajhg.2014.10.003","volume":"95","author":"R Buchert","year":"2014","unstructured":"Buchert R, Tawamie H, Smith C, Uebe S, Innes AM, Al Hallak B, et al. A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency. Am J Hum Genet. 2014;95(5):602\u201310.","journal-title":"Am J Hum Genet"},{"issue":"20","key":"3660_CR5","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1093\/hmg\/ddv305","volume":"24","author":"T Bar\u00f8y","year":"2015","unstructured":"Bar\u00f8y T, Koster J, Str\u00f8mme P, Ebberink MS, Misceo D, Ferdinandusse S, et al. A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform. Hum Mol Genet. 2015;24(20):5845\u201354.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"3660_CR6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ajmg.a.37961","volume":"173","author":"AL Duker","year":"2017","unstructured":"Duker AL, Niiler T, Eldridge G, Brereton NH, Braverman NE, Bober MB. Growth charts for individuals with rhizomelic chondrodysplasia punctata. Am J Med Genet A. 2017;173(1):108\u201313.","journal-title":"Am J Med Genet A"},{"key":"3660_CR7","unstructured":"Braverman NE, Steinberg SJ, Fallatah W, Duker A, Bober MB. Rhizomelic chondrodysplasia punctata type 1. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, editors. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle; 1993 [cited 2024 May 12]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1270\/"},{"key":"3660_CR8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1750-1172-8-174","volume":"8","author":"AM Bams-Mengerink","year":"2013","unstructured":"Bams-Mengerink AM, Koelman JH, Waterham H, Barth PG, Poll-The BT. The neurology of rhizomelic chondrodysplasia punctata. Orphanet J Rare Dis. 2013;8:174.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"3660_CR9","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1097\/BPO.0000000000001014","volume":"39","author":"O Abousamra","year":"2019","unstructured":"Abousamra O, Kandula V, Duker AL, Rogers KJ, Bober MB, Mackenzie WG. Cervical spine deformities in children with rhizomelic chondrodysplasia punctata. J Pediatr Orthop. 2019;39(9):e680\u20136.","journal-title":"J Pediatr Orthop"},{"issue":"4","key":"3660_CR10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/ajmg.a.20009","volume":"118A","author":"AL White","year":"2003","unstructured":"White AL, Modaff P, Holland-Morris F, Pauli RM. Natural history of rhizomelic chondrodysplasia punctata. Am J Med Genet A. 2003;118A(4):332\u201342.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"3660_CR11","doi-asserted-by":"crossref","first-page":"dmm042499","DOI":"10.1242\/dmm.042499","volume":"13","author":"W Fallatah","year":"2020","unstructured":"Fallatah W, Smith T, Cui W, Jayasinghe D, Di Pietro E, Ritchie SA, et al. Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctata. Dis Model Mech. 2020;13(1):dmm042499.","journal-title":"Dis Model Mech"},{"key":"3660_CR12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1476-511X-10-182","volume":"10","author":"PL Wood","year":"2011","unstructured":"Wood PL, Khan MA, Smith T, Ehrmantraut G, Jin W, Cui W, et al. In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor. Lipids Health Dis. 2011;10:182.","journal-title":"Lipids Health Dis"},{"issue":"7","key":"3660_CR13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jval.2017.05.015","volume":"20","author":"K Benjamin","year":"2017","unstructured":"Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2017;20(7):838\u201355.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"3660_CR14","unstructured":"Research C. for DE and. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. FDA; 2020 [cited 2024 May 12]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims"},{"issue":"8","key":"3660_CR15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2011;14(8):967\u201377.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"1","key":"3660_CR16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3660_CR17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1477-7525-12-15","volume":"12","author":"A Br\u00e9dart","year":"2014","unstructured":"Br\u00e9dart A, Marrel A, Abetz-Webb L, Lasch K, Acquadro C. Interviewing to develop patient-reported outcome (PRO) measures for clinical research: eliciting patients\u2019 experience. Health Qual Life Outcomes. 2014;12(1):15.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"3660_CR18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","volume":"62","author":"S Elo","year":"2008","unstructured":"Elo S, Kyng\u00e4s H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107\u201315.","journal-title":"J Adv Nurs"},{"issue":"3","key":"3660_CR19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/03098260600927575","volume":"30","author":"RL Breen","year":"2006","unstructured":"Breen RL. A practical guide to focus-group research. J Geogr High Educ. 2006;30(3):463\u201375.","journal-title":"J Geogr High Educ"},{"key":"3660_CR20","unstructured":"Bogdan RC, Biklen SK. Qualitative research for education an introduction to theory and methods (5th ed.). Pearson; 2007."},{"issue":"2","key":"3660_CR21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2307\/1318573","volume":"22","author":"JJ Gnida","year":"1994","unstructured":"Gnida JJ. Review of sociology of sport. Teach Sociol. 1994;22(2):208\u201310.","journal-title":"Teach Sociol"},{"key":"3660_CR22","doi-asserted-by":"crossref","unstructured":"Lincoln YS, Guba EG. Naturalistic inquiry. SAGE; 1985. 422 p.","DOI":"10.1016\/0147-1767(85)90062-8"},{"key":"3660_CR23","doi-asserted-by":"crossref","unstructured":"Knafl KA, Patton MQ, Sage. 532 pp., $28.00 (hardcover). Res Nurs Health. 1991;14(1):73\u20134.","DOI":"10.1002\/nur.4770140111"},{"issue":"2","key":"3660_CR24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/01490400.2015.1127189","volume":"39","author":"JJ Vaske","year":"2017","unstructured":"Vaske JJ, Beaman J, Sponarski CC. Rethinking internal consistency in Cronbach\u2019s alpha. Leis Sci. 2017;39(2):163\u201373.","journal-title":"Leis Sci"},{"issue":"2","key":"3660_CR25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1399-0004.1990.tb03554.x","volume":"38","author":"TD Wardinsky","year":"1990","unstructured":"Wardinsky TD, Pagon RA, Powell BR, McGillivray B, Stephan M, Zonana J, et al. Rhizomelic chondrodysplasia punctata and survival beyond one year: a review of the literature and five case reports. Clin Genet. 1990;38(2):84\u201393.","journal-title":"Clin Genet"},{"key":"3660_CR26","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Rev. 1976. Rockville, Md: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. 603 p."},{"issue":"10\u201312","key":"3660_CR27","first-page":"15","volume":"18","author":"J Busner","year":"2021","unstructured":"Busner J, Pandina G, Domingo S, Berger AK, Acosta MT, Fisseha N, et al. Clinician- and patient-reported endpoints in CNS orphan drug clinical trials: ISCTM position paper on best practices for endpoint selection, validation, training, and standardization. Innov Clin Neurosci. 2021;18(10\u201312):15\u201322.","journal-title":"Innov Clin Neurosci"},{"issue":"6","key":"3660_CR28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40271-015-0114-3","volume":"8","author":"A Gater","year":"2015","unstructured":"Gater A, Rofail D, Marshall C, Tolley C, Abetz-Webb L, Zarit SH, et al. Assessing the impact of caring for a person with schizophrenia: development of the schizophrenia caregiver questionnaire. Patient. 2015;8(6):507\u201320.","journal-title":"Patient"},{"issue":"1","key":"3660_CR29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12955-021-01813-w","volume":"19","author":"H Staunton","year":"2021","unstructured":"Staunton H, Trennery C, Arbuckle R, Guridi M, Zhuravleva E, Furlong P, et al. Development of a clinical global impression of change (CGI-C) and a caregiver global impression of change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy. Health Qual Life Outcomes. 2021;19(1):184.","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"3660_CR30","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/epi.17000","volume":"62","author":"AD Patel","year":"2021","unstructured":"Patel AD, Mazurkiewicz-Be\u0142dzi\u0144ska M, Chin RF, Gil-Nagel A, Gunning B, Halford JJ, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: results of a long-term open-label extension trial. Epilepsia. 2021;62(9):2228\u201339.","journal-title":"Epilepsia"},{"key":"3660_CR31","doi-asserted-by":"crossref","first-page":"109805","DOI":"10.1016\/j.yebeh.2024.109805","volume":"156","author":"O Devinsky","year":"2024","unstructured":"Devinsky O, Hyland K, Loftus R, Nortvedt C, Nabbout R. Placebo response in patients with Dravet syndrome: post-hoc analysis of two clinical trials. Epilepsy Behav EB. 2024;156:109805.","journal-title":"Epilepsy Behav EB"},{"issue":"6","key":"3660_CR32","first-page":"1013","volume":"21","author":"JM Norquist","year":"2012","unstructured":"Norquist JM, Girman C, Fehnel S, DeMuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2012;21(6):1013\u201320.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"key":"3660_CR33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-016-0483-x","volume":"14","author":"JE Ware","year":"2016","unstructured":"Ware JE, Gandek B, Guyer R, Deng N. Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL disease impact scale (QDIS\u00ae). Health Qual Life Outcomes. 2016;14:84.","journal-title":"Health Qual Life Outcomes"},{"key":"3660_CR34","first-page":"27","volume":"37","author":"NA Zeltner","year":"2017","unstructured":"Zeltner NA, Baumgartner MR, Bondarenko A, Ensenauer R, Karall D, K\u00f6lker S, et al. Development and psychometric evaluation of the MetabQoL 1.0: a quality of life questionnaire for paediatric patients with intoxication-type inborn errors of metabolism. JIMD Rep. 2017;37:27\u201335.","journal-title":"JIMD Rep"},{"issue":"1\u20132","key":"3660_CR35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/10497323231205419","volume":"34","author":"HR Davidson","year":"2024","unstructured":"Davidson HR, Gelles S, Keller KR, Zajdel M, Koehly LM. Becoming a rare disease parent: an interpretative phenomenological analysis of parent-caregivers\u2019 postpartum experiences. Qual Health Res. 2024;34(1\u20132):126\u201340.","journal-title":"Qual Health Res"},{"issue":"1","key":"3660_CR36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13023-022-02561-w","volume":"17","author":"K Sandilands","year":"2022","unstructured":"Sandilands K, Williams A, Rylands AJ. Carer burden in rare inherited diseases: a literature review and conceptual model. Orphanet J Rare Dis. 2022;17(1):428.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3660_CR37","doi-asserted-by":"crossref","first-page":"e0277741","DOI":"10.1371\/journal.pone.0277741","volume":"18","author":"F Wakeel","year":"2023","unstructured":"Wakeel F, Hannah J, Gorfinkel L. Stress, coping, and quality of life in the United States during the COVID-19 pandemic. PLoS ONE. 2023;18(5):e0277741.","journal-title":"PLoS ONE"},{"key":"3660_CR38","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.2147\/CMAR.S175210","volume":"10","author":"M Chabowski","year":"2018","unstructured":"Chabowski M, Jankowska-Pola\u0144ska B, Lomper K, Janczak D. The effect of coping strategy on quality of life in patients with NSCLC. Cancer Manag Res. 2018;10:4085\u201393.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"3660_CR39","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ajmg.a.33380","volume":"152A","author":"JS Cohen","year":"2010","unstructured":"Cohen JS, Biesecker BB. Quality of life in rare genetic conditions: a systematic review of the literature. Am J Med Genet A. 2010;152A(5):1136\u201356.","journal-title":"Am J Med Genet A"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03660-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03660-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03660-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:45:23Z","timestamp":1743399923000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03660-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3660"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03660-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4650843\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study. Approval for the study was granted by the Montclair State University Institutional Review Board (IRB-FY-17-18-1045).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TMS and SAR are paid employees of Med-Life Discoveries LP, and this work was funded by Med-Life Discoveries LP.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}